Roche’s Genentech signed a wide-ranging bispecific antibody discovery and development collaboration with Earendil Labs, paying $55 million upfront. The agreement covers multiple bispecific programs in oncology, with milestones that could push total deal value above $1.5 billion. For Earendil, the pact provides near-term funding and a credible pathway for platform-to-pipeline conversion through Genentech’s clinical and regulatory capabilities. For Genentech, the deal adds additional “options” in a competitive bispecific landscape where differentiated discovery platforms can shorten time to clinic. The structure signals continued corporate appetite for external bispecific innovation—particularly for oncology targets where potency, half-life engineering and manufacturability can determine competitive positioning.